These observations suggest that pre-treatment evaluation of membrane LAT1 in curatively-resected CRC samples could be a marker to predict high-risk CRC cases with short survival rates, high recurrence rates, and poor response to adjuvant chemotherapy, including oxaliplatin. This evidence concerns the gene SLC7A5 and colorectal carcinoma.